Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti‐Tumour Potency on Prostate Cancer Cells. (26th July 2012)

• Record Type: Journal Article
• Authors: Fagone, Paolo; Donia, Marco; Mangano, Katia; Quattrocchi, Cinzia; Mammana, Santa; Coco, Marinella; Libra, Massimo; McCubrey, James A.; Nicoletti, Ferdinando
• Is Part Of: Basic & clinical pharmacology & toxicology. Volume 112:Number 1(2013:Jan.)
• Page Start: 63
• Page End: 69
• Publication Date: 2012-07-26
• Subjects: Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology -- Periodicals; Toxicology -- Periodicals; Pharmacology, Clinical -- Periodicals; Computer network resources; Electronic journals; 615.1
• DOI: 10.1111/j.1742-7843.2012.00923.x
• Languages: English
• ISSNs: 1742-7835

Abstract

<abstract abstract-type="main" id="bcpt923-abs-0001"> <title>Abstract</title> <p>Rapamycin is a macrocyclic lactone currently used for the treatment of cancer and for the prevention of transplant rejection. The primary pharmacological mode of action of rapamycin occurs through the inhibition (blocking) of the mammalian target of rapamycin (mTOR). By doing so, rapamycin interferes with the phosphoinositide 3‐kinase (PI3K)‐Akt‐mTOR axis that controls several cellular functions involving cell growth, proliferation and angiogenesis. The frequent activation of the phosphoinositide 3‐kinase (PI3K)/AKT pathway in advanced prostate cancer has provided a rationale for the use of mTOR inhibitors in this setting. We carried out a comparative study on the effects of rapamycin and temsirolimus on the <italic>in vitro</italic> and <italic>in vivo</italic> growth of the prostate cancer cell lines, LnCap and PC3. Our results demonstrate that rapamycin and temsirolimus exert similar <italic>in vitro</italic> and <italic>in vivo</italic> anti‐proliferative effects against prostate cancer cells.</p> </abstract>